A SURVEY OF ADVERSE EVENTS FOLLOWING IMMUNIZATION OF COVID-19 IN HEALTH-CARE WORKERS AT TERTIARY CARE HOSPITAL IN SOUTH GUJARAT REGION

CHAUDHARI ARCHANABAHEN G; PATEL BRIJALKUMAR S; TANDEL KIRTIDA R

doi:10.22159/ajpcr.2024v17i8.51554

Authors

CHAUDHARI ARCHANABAHEN G Department of Pharmacology, GMERS Medical College, Valsad, Gujarat, India. https://orcid.org/0009-0005-6095-1064
PATEL BRIJALKUMAR S Department of Pharmacology, GMERS Medical College, Navsari, Gujarat, India. https://orcid.org/0000-0002-7781-6564
TANDEL KIRTIDA R Department of Pharmacology, GMERS Medical College, Valsad, Gujarat, India.

DOI:

https://doi.org/10.22159/ajpcr.2024v17i8.51554

Keywords:

Adverse events following immunization, COVID-19,, COVISHIELD, COVAXIN, Health-care workers

Abstract

Objectives: The aim of the study was to evaluate adverse events following immunization (AEFI) among the health-care workers (HCWs) who received both doses of the COVID-19 vaccine either COVISHIELD or COVAXIN.

Methods: A questionnaire-based retrospective cross-sectional survey was carried out at the tertiary care teaching hospital of South Gujarat after getting approval from the Institutional Human Ethics Committee. A total of 542 HCWs who received two doses of vaccine were enrolled. Vaccine-related adverse effects and association of AEFI with demographic variables were determined.

Results: Fever, pain at the injection site, and body aches were the common adverse events reported by the participants following both doses of COVISHIELD and COVAXIN. Most of the AEFIs were reported within 6–12 h of vaccination after the 1st and 2nd doses. We found no association of AEFI with comorbidity and previous COVID-19 infection. A significant association of AEFI was found with gender, age groups, and occupation (p<0.05).

Conclusion: Most of the adverse events were non-serious and reported within 6–12 h of vaccination. Only few adverse events were reported after 24 h of vaccination and no serious AEFI was reported. Younger age groups, females, and HCWs are at higher risk of AEFI. Precaution needs to be taken while vaccinating these individuals.

Downloads

Download data is not yet available.

References

World Health Organization. Coronavirus (COVID-19) Dashboard. Available from: https://covid19.who. int/?adgroupsurvey={adgroupsurvey}&gclid=eaiaiqobchmi7azc2la__ wivrcbych3daavxeaayasabeglg0pd_bwe [Last accessed on 2023 June 12].

Ministry of Health and Family Welfare. Government of India. Information Regarding COVID-19 Vaccine. Available from: https:// www.mohfw.gov.in/covid_vaccination/vaccination/index.html [Last accessed on 2023 Mar 12].

Serum Institute of India. Fact Sheet for Vaccine Recipient Approved for Restricted Use in Emergency Situation of ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant). Available from: https://www. seruminstitute.com/pdf/covishield_fact_sheet.pdf [Last accessed on 2023 Feb 16].

Bharat Biotech. Fact Sheet for Vaccine Recipients and Care Givers Approved for Restricted Use in Emergency Situation of COVID-19. Available from: https://www.bharatbiotech.com/images/covaxin/ covaxin-factsheet.pdf [Last accessed on 2023 Feb 16].

World Health Organization. Adverse Events Following Immunization (AEFI). Available from: https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/aefi/aefi [Last accessed on 2023 Feb 16].

Godlee F. What should we do about vaccine hesitancy? BMJ. 2019;365:14044. doi: 10.1136/bmj.l4044

Basavaraja CK, Sebastian J, Ravi MD, John SB. Adverse events following COVID-19 vaccination: First 90 days of experience from a tertiary care teaching hospital in South India. Ther Adv Vaccines Immunother. 2021 Nov;9:1-12. doi: 10.1177/25151355211055833, PMID 34841193

Konda VC, Gokul T, Poojitha MP, Rao KU. Adverse events following immunization to Covid-19 vaccines in a tertiary care hospital-A descriptive study. Biomed Pharmacol J. 2021;14(4):2149-56. doi: 10.13005/bpj/2312

Mer RJ, Kakasaniya GG, Acharya TA, Mehta DS. A participant centered surveillance of adverse events following coronavirus disease immunization phase 1 at a tertiary care teaching hospital. Natl J Physiol Pharm Pharmacol. 2022;12(3):312-6.

Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials. Lancet. 2021;397(10277):881-91. doi: 10.1016/ S0140-6736(21)00432-3, PMID 33617777

Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020;396(10267):1979-93. doi: 10.1016/S0140- 6736(20)32466-1

Tequare MH, Abraha HE, Adhana MT, Tekle TH, Belayneh EK, Gebresilassie KB, et al. Adverse events of Oxford/AstraZeneca’’s COVID-19 vaccine among health care workers of Ayder Comprehensive Specialized Hospital, Tigray, Ethiopia. IJID Reg. 2021;1:124-9. doi: 10.1016/j.ijregi.2021.10.013, PMID 35721767

Chaudhary C, Singh M, Khan MN, Anand BK, Saini S. Adverse events following immunization against COVID-19 among healthcare workers: An observational study in Haryana, India. Asian J Med Sci. 2022;13(3):23-9. doi: 10.3126/ajms.v13i3.41073

Dhamnetiya D, Kumar P, Goel SK, Jha A, Bharatwal AA, Singh S, et al. Adverse events following immunization of chadox1 ncov-19 vaccine among health care workers of a tertiary care hospital of north India. Res Square. 2022;1(3):1-28.

Kamal D, Thakur V, Nath N, Malhotra T, Gupta A, Batlish R. Adverse events following ChAdOx1 nCoV-19 vaccine (COVISHIELD) amongst health care workers: A prospective observational study. Med J Armed Forces India. 2021;77(Suppl 2):283-8. doi: 10.1016/j. mjafi.2021.06.014, PMID 34334895

Kaur U, Ojha B, Pathak BK, Singh A, Giri KR, Singh A, et al. A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers-first results from India. EClinicalmedicine. 2021;38:101038. doi: 10.1016/j. eclinm.2021.101038, PMID 34505032

Khalil MM, Mahbub-Uz-Zaman K, Hossain AS, Ahmed F, Chowdhury MF, Khan ST, et al. Adverse events following Covishield vaccination among adult population in Bangladesh. SN Compr Clin Med. 2021;3(11):2207-13. doi: 10.1007/s42399-021-01021-z, PMID 34368624

Parida SP, Sahu DP, Singh AK, Alekhya G, Subba SH, Mishra A, et al. Adverse events following immunization of COVID‐19 (Covaxin) vaccine at a tertiary care center of India. J Med Virol. 2022;94(6):2453-9. doi: 10.1002/jmv.27655, PMID 35149993